These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia. Sirota P; Mosheva T; Shabtay H; Giladi N; Korczyn AD Am J Psychiatry; 2000 Feb; 157(2):287-9. PubMed ID: 10671405 [TBL] [Abstract][Full Text] [Related]
6. Neuroleptic-induced emesis: a new indication for clozapine? Bustillo JR; Buchanan RW Biol Psychiatry; 1995 Aug; 38(3):194-5. PubMed ID: 7578665 [No Abstract] [Full Text] [Related]
7. Why neuroleptic withdrawal in schizophrenia? Carpenter WT; Tamminga CA Arch Gen Psychiatry; 1995 Mar; 52(3):192-3. PubMed ID: 7872843 [No Abstract] [Full Text] [Related]
8. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Gilbert PL; Harris MJ; McAdams LA; Jeste DV Arch Gen Psychiatry; 1995 Mar; 52(3):173-88. PubMed ID: 7872841 [No Abstract] [Full Text] [Related]
9. Clozapine treatment of psychosis in patients with tardive dystonia: report of three cases. Friedman JH Mov Disord; 1994 May; 9(3):321-4. PubMed ID: 7913739 [TBL] [Abstract][Full Text] [Related]
10. Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures. Gardos G; Cole JO; Rapkin RM; LaBrie RA; Baquelod E; Moore P; Sovner R; Doyle J Arch Gen Psychiatry; 1984 Nov; 41(11):1030-5. PubMed ID: 6149737 [TBL] [Abstract][Full Text] [Related]
12. Effects of neuroleptic reduction in schizophrenic outpatients receiving high doses. Leblanc G; Cormier H; Gagné MA; Vaillancourt S Can J Psychiatry; 1994 May; 39(4):223-9. PubMed ID: 7913872 [TBL] [Abstract][Full Text] [Related]
13. Treatment of clozapine-associated tardive dyskinesia. Lin CC; Bai YM; Chen JY; Wang YC; Liou YJ Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):599-600. PubMed ID: 17920744 [No Abstract] [Full Text] [Related]
14. Extrapyramidal syndromes and new antipsychotic drugs: findings in patients and non-human primate models. Casey DE Br J Psychiatry Suppl; 1996 May; (29):32-9. PubMed ID: 8733821 [No Abstract] [Full Text] [Related]
15. Neuroleptic plasma levels and tardive dyskinesia: a possible link? Nasrallah HA Schizophr Bull; 1980; 6(1):4-7. PubMed ID: 6102792 [TBL] [Abstract][Full Text] [Related]
16. [Current data on neurologic sequelae caused by neuroleptics]. Krebs MO Encephale; 1995 Jun; 21 Spec No 3():49-52. PubMed ID: 7628342 [TBL] [Abstract][Full Text] [Related]
17. Prevention and management of tardive dyskinesia. Jeste DV; Wyatt RJ J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):14-8. PubMed ID: 2858473 [TBL] [Abstract][Full Text] [Related]
18. [Antiparkinson drugs in neuroleptic treatment: comparative study of progressive and abrupt withdrawal]. Ben Hadj Ali B; Dogui M; Ben Ammou S; Lôo H Encephale; 1995; 21(3):209-15. PubMed ID: 7649071 [TBL] [Abstract][Full Text] [Related]
19. Withdrawal-emergent dyskinesia in patients with schizophrenia during antipsychotic discontinuation. Schultz SK; Miller DD; Arndt S; Ziebell S; Gupta S; Andreasen NC Biol Psychiatry; 1995 Dec; 38(11):713-9. PubMed ID: 8580223 [TBL] [Abstract][Full Text] [Related]
20. Neuroleptic withdrawal in schizophrenic patients. Baldessarini RJ; Viguera AC Arch Gen Psychiatry; 1995 Mar; 52(3):189-92. PubMed ID: 7872842 [No Abstract] [Full Text] [Related] [Next] [New Search]